1. Generics Bulletin
  2. >>Business
  3. >>Deals

Winlevi Attracts Interest From Multiple Industry Players

Canadian Launch From Sun Accompanied By Fresh Deals With Glenmark And Hikma

 
• By Dave Wallace

As Sun Pharma announces a Canadian launch for its licensed Winlevi clascoterone cream dermatology asset, the firm’s originating partner Cassiopea has struck further deals with Hikma and Glenmark for the acne treatment to be sold in Europe, the MENA region and South Africa.

Handshake
Deals have taken place around the globe for Winlevi

Fresh deals with off-patent industry players Glenmark and Hikma have been seen for Cassiopea’s Winlevi (clascoterone) acne treatment, in Europe and South Africa and in the Middle East and North Africa region respectively, at the same time as existing North America licensee Sun Pharma announced a launch in Canada.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

 
• By Dave Wallace

India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.

More from Business

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By Adam Zamecnik

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.